Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947399218> ?p ?o ?g. }
Showing items 1 to 45 of
45
with 100 items per page.
- W2947399218 abstract "e18111 Background: The addition of pertuzumab (P) to a neoadjuvant trastuzumab (H) plus chemotherapy combination has been shown to significantly improve the pathologic complete response rate (pCR) in localized HER2+ breast cancer; however, minorities have been under-represented in these trials. Racial/ethnic disparities have also been shown to affect outcomes of cancer treatment. This study is aimed to assess the impact of neoadjuvant dual HER2-blockade in an unselected minority-enriched population. Methods: A retrospective chart review was conducted of women with stage I to III HER2+ breast cancer who received neoadjuvant treatment between 2007 and 2017 at an academic institution and its affiliated safety net health system. Data on stage, chemotherapy, race/ethnicity, site of therapy (academic vs safety net hospital), and hormone receptor status were collected. All patients underwent surgery after completion of neoadjuvant chemotherapy. pCR was defined as ypT0/is, ypN0. Chi-squared test and univariate/multivariate logistic regression were used for statistical analysis. Results: The study population included 261 women with the following race/ethnic distribution: 37.7% Non-Hispanic Whites, 34.6% Hispanics, 20.6% Blacks, and 7% other racial/ethnic origin. Ninety-five patients (36%) received chemotherapy-H vs 166 patients (64%) received chemotherapy-HP. Patients at the safety net health system had higher stage at diagnosis compared to the academic site. Site of care and race/ethnicity did not impact the choice of neoadjuvant treatment. The pCR rate was significantly higher for the chemotherapy-HP group (55.4%) compared to the chemotherapy-H group (34.7%) (p = 0.001). There was no association between race/ethnicity, or site of treatment (academic vs safety net), and the probability of achieving pCR. Multivariate analysis showed only dual anti-HER2 therapy (OR: 2.67, CI: 1.55-4.59, p = 0.0004) and hormone-receptor negative status (OR: 2.18, CI: 1.30-3.67, p = 0.0031) to correlate with pCR. Conclusions: Neoadjuvant dual anti-HER2 therapy was more likely to result in a pCR in our minority enriched population. Our data also suggests the combination of chemotherapy-HP confers similar benefit irrespective of race/ethnicity or site of care." @default.
- W2947399218 created "2019-06-07" @default.
- W2947399218 creator A5008905848 @default.
- W2947399218 creator A5032510985 @default.
- W2947399218 creator A5061962242 @default.
- W2947399218 creator A5065222917 @default.
- W2947399218 creator A5067822524 @default.
- W2947399218 creator A5069001170 @default.
- W2947399218 date "2019-05-20" @default.
- W2947399218 modified "2023-09-24" @default.
- W2947399218 title "Impact of dual anti-HER2 therapy on pathologic complete response rate in breast cancer in a minority-enriched population." @default.
- W2947399218 doi "https://doi.org/10.1200/jco.2019.37.15_suppl.e18111" @default.
- W2947399218 hasPublicationYear "2019" @default.
- W2947399218 type Work @default.
- W2947399218 sameAs 2947399218 @default.
- W2947399218 citedByCount "1" @default.
- W2947399218 countsByYear W29473992182020 @default.
- W2947399218 crossrefType "journal-article" @default.
- W2947399218 hasAuthorship W2947399218A5008905848 @default.
- W2947399218 hasAuthorship W2947399218A5032510985 @default.
- W2947399218 hasAuthorship W2947399218A5061962242 @default.
- W2947399218 hasAuthorship W2947399218A5065222917 @default.
- W2947399218 hasAuthorship W2947399218A5067822524 @default.
- W2947399218 hasAuthorship W2947399218A5069001170 @default.
- W2947399218 hasConcept C121608353 @default.
- W2947399218 hasConcept C126322002 @default.
- W2947399218 hasConcept C143998085 @default.
- W2947399218 hasConcept C2908647359 @default.
- W2947399218 hasConcept C530470458 @default.
- W2947399218 hasConcept C71924100 @default.
- W2947399218 hasConcept C99454951 @default.
- W2947399218 hasConceptScore W2947399218C121608353 @default.
- W2947399218 hasConceptScore W2947399218C126322002 @default.
- W2947399218 hasConceptScore W2947399218C143998085 @default.
- W2947399218 hasConceptScore W2947399218C2908647359 @default.
- W2947399218 hasConceptScore W2947399218C530470458 @default.
- W2947399218 hasConceptScore W2947399218C71924100 @default.
- W2947399218 hasConceptScore W2947399218C99454951 @default.
- W2947399218 hasLocation W29473992181 @default.
- W2947399218 hasOpenAccess W2947399218 @default.
- W2947399218 hasPrimaryLocation W29473992181 @default.
- W2947399218 isParatext "false" @default.
- W2947399218 isRetracted "false" @default.
- W2947399218 magId "2947399218" @default.
- W2947399218 workType "article" @default.